PFND

Pathfinder Cell Therapy, Inc. PFND

PFND
Pathfinder Cell Therapy, Inc. XENO
Xeno Transplants Corporation AURX
Nuo Therapeutics, Inc. IMUC
EOM Pharmaceuticals Holdings, Inc. HLVX
HilleVax, Inc. PZRXQ
PhaseRx, Inc. GNLKQ
GeneLink, Inc. TNGNQ
Tengion, Inc. RGDXQ
Response Genetics, Inc FPMI
FluoroPharma Medical, Inc.

Résultat net

EBITDA

P/E Ratio

Capitalisation

Performance

Periode PFND XENO AURX IMUC HLVX PZRXQ GNLKQ TNGNQ RGDXQ FPMI
6M 0.00 % 0.00 % 40.63 % -39.60 % 24.40 % -50.00 % -60.00 % 0.00 % 0.00 % 0.00 %
YTD 0.00 % 0.00 % 61.87 % -46.75 % 0.48 % -50.00 % -60.00 % 0.00 % 0.00 % 0.00 %
1Y 0.00 % 0.00 % 275.00 % -23.08 % 17.42 % -50.00 % -60.00 % 0.00 % 0.00 % 0.00 %
3Y 0.00 % -50.00 % -44.17 % -87.67 % -87.45 % 0.00 % -60.00 % 900.00 % 0.00 % -97.83 %
5Y -96.95 % -96.67 % 1 395.02 % -80.85 % -89.05 % -93.33 % -94.29 % 900.00 % -94.12 % -95.45 %
10Y -98.75 % -97.44 % 650.00 % -80.85 % -89.05 % -100.00 % -86.67 % 900.00 % -98.67 % -99.97 %
Depuis le début -99.97 % -99.90 % 650.00 % -80.85 % -89.05 % -100.00 % -100.00 % 900.00 % -100.00 % -99.99 %

Dividende